EQL Pharma Investor Relations

Press Releases

EQL Pharma's CEO increases his holding in the company

EQL Pharma's CEO, Axel Schörling, has increased his stake in the company. During the period 22-24 May, Axel Schörling has bought 53,903 shares in the Company at a volume-weighted average price of S...

Year-end Report April 2023 – March 2024

Regulatory

Good growth and record amount of launches January - March 2024 · Consolidated sales during the fourth quarter, January to March amounted to SEK 78.1 (60.3) million, an increase of 30%. Adjusted...

Se all

Presentations

Interim Report Q3 2023/2024 (in Swedish)

Interim Report Q2 2023/2024 (in Swedish)

Se all